Cardiff Oncology, Inc.
CRDF
$2.41
-$0.03-1.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -51.02M | -48.85M | -45.43M | -42.98M | -40.86M |
| Total Depreciation and Amortization | 654.00K | 665.00K | 673.00K | 680.00K | 686.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.75M | 4.42M | 4.16M | 3.82M | 3.37M |
| Change in Net Operating Assets | 3.77M | 1.02M | 2.90M | 3.92M | 4.74M |
| Cash from Operations | -41.85M | -42.75M | -37.69M | -34.57M | -32.07M |
| Capital Expenditure | -26.00K | 0.00 | -80.00K | -88.00K | -403.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -24.46M | -5.49M | 13.81M | 22.87M | 36.44M |
| Cash from Investing | -24.49M | -5.49M | 13.73M | 22.78M | 36.03M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 51.62M | 53.68M | 53.78M | 9.59M | 2.17M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 51.62M | 53.68M | 53.78M | 9.59M | 2.17M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.72M | 5.44M | 29.82M | -2.20M | 6.13M |